Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$0.9 - $1.83 $540 - $1,098
600 New
600 $744,000
Q4 2020

Feb 16, 2021

BUY
$15.77 - $19.03 $9,462 - $11,418
600 New
600 $10,000
Q3 2020

Oct 23, 2020

SELL
$16.59 - $24.79 $9,954 - $14,874
-600 Closed
0 $0
Q2 2019

Jul 25, 2019

SELL
$31.0 - $36.3 $21,204 - $24,829
-684 Reduced 53.27%
600 $0
Q4 2018

Jan 29, 2019

SELL
$30.43 - $56.65 $164,565 - $306,363
-5,408 Reduced 80.81%
1,284 $42,000
Q3 2018

Nov 09, 2018

BUY
$46.46 - $68.49 $283,034 - $417,241
6,092 Added 1015.33%
6,692 $0
Q1 2018

Apr 18, 2018

BUY
$57.4 - $108.44 $34,440 - $65,064
600 New
600 $0

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $152M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Atlas Capital Advisors LLC Portfolio

Follow Atlas Capital Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atlas Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atlas Capital Advisors LLC with notifications on news.